Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peresolimab in moderately-to-severely active rheumatoid arthritis
NCT05516758Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of peresolimab in rheumatoid arthritis (RA) (7 arms), sponsored by Eli Lilly and Company. Primary endpoint: 20% Improvement in American College of Rheumatology Criteria at 12 weeks. Started Aug 2022; status: terminated.
02
Drugs
peresolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05516758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516758.